Novartis Ag

Asana Biosciences, LLC

Aurigene Discovery Technologies Limited

Debiopharm S.a.

Merck Patent Gmbh

Saumitra Sengupta

Mark G Bock

Christoph Gaul

Roger Astbury Smith

Scott Kevin Thompson

Sunil Kumar Panigrahi

Venkateshwar Rao Gummadi

Vijay Potluri

Sanjeeva P Reddy

Prabhakara Rao Nadipalli

Vijay Kumar Nyavanandi

Tyler M John

Maximilien Murone

Hosahalli Subramanya

Shankar Jayaram Shetty

Andrès Mc Allister

Ramesh Kumar Sistla

Subramanya Hosahalli

Didier Roche

Francis Contard

Henrik Moebitz

Ingo Kober

Serge Christmann-Franck

Subramanya Hoshalli

Gisèle Mautino

Gummadi Venkateshwar Rao

Venkateshwar Rao Gunmadi

Mark Gary Bock

Ramesh Sistla

Gisele Mautino

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R, and Rto Rare defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer. 

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R, and Rto Rare defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/the disease is cancer. 

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R, R, R, R, Rand Rare as defined herein. The compounds of the present invention have been found to be useful as 17&#x3b1;-hydroxylase/C-lyase inhibitors.

17a-hydroxylase/C17,20-lyase inhibitors

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R, R, R, R, Rand Rare as defined herein. The compounds of the present invention have been found to be useful as 17&#x3b1;-hydroxylase/C-lyase inhibitors. 

[object Object]

The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3. 

Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R, R, R, R, R, R, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided. 

The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R, R, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17&#x3b1;-hydroxylase/C-lyase inhibitors.

Inhibitors of CYP 17

The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I). 

Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators

Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors

Growing community of inventors

Kolkata, India

Saumitra Sengupta